Teliso-V is also being evaluated against docetaxel in the randomized phase 3 TeliMET NSCLC-01 trial in patients with previously treated non-squamous NSCLC who express c-Met and are wild-type for EGFR in combination with osimertinib in the phase 1 M14-237 trial [59]. Here, MET is linked to non-small cell lung carcinoma.